ABK Biomedical
PrivateLast Round
Series D
Oct 14, 2025
Total Funding Raised
$105.55M
Company Overview
ABK Biomedical operates in Healthcare & Life Sciences and is based in Halifax. Its latest recorded funding round was a Series D round in October 2025.
ABK Biomedical is a medical technology company that develops innovative microspheres to enhance the treatment of hypervascular tumors through improved targeting of tumor vascularity and tissue.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Medical Imaging, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ABK Biomedical Comparables
Compare ABK Biomedical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sirtex Medical | 88% | |
| Cortex, Inc. | 83% | |
| NED Medical, Inc. | 82% |
For institutional investors. Book with your work email.
ABK Biomedical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Oct 14, 2025 | ||||
| Series C | Dec 6, 2022 | ||||
| Series B | Apr 8, 2019 | ||||
| Grant | Feb 22, 2018 | ||||
| Series A | Aug 1, 2017 | ||||
Seed | Oct 24, 2012 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ABK Biomedical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovacorp | Seed, Series A |
| F-Prime Capital | Series C, Series D, Series B |
| Eight Roads Ventures | Series C, Series D |
| Innovacorp | Seed, Series A |
| Santé Ventures | Series D, Series C |
| Atlantic Canada Opportunities Agency | Grant, Seed |
| F-Prime Capital | Series C, Series D, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 8, 2026
Building a plant in Missouri for Eye90 microsphere technology.
- Apr 8, 2026
Partnering with COR Development to build a GMP facility in Missouri.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- expands_facilitiesOct 2, 2026
ABK Biomedical Inc. began construction on a future commercial medical technology manufacturing facility in Missouri on Oct 2nd '26.
For institutional investors. Book with your work email.
ABK Biomedical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ABK Biomedical's valuation, stock price, and market status.
Is ABK Biomedical a public or private company?
ABK Biomedical is a private company.
What is the current stock price of ABK Biomedical?
ABK Biomedical is a private company, so its shares have no public market price. Caplight tracks ABK Biomedical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ABK Biomedical worth (valuation)?
Valuation information for ABK Biomedical is not publicly available.
Can I buy ABK Biomedical stock?
ABK Biomedical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ABK Biomedical's last funding round?
ABK Biomedical's most recent funding round was Series D on October 14, 2025.
Who are the main investors in ABK Biomedical?
Key investors in ABK Biomedical include F-Prime Capital, Santé Ventures, F-Prime Capital, Sante, Santé Ventures.
Will ABK Biomedical IPO soon?
No public IPO plans have been announced for ABK Biomedical.
How can I track ABK Biomedical secondary market activity?
Caplight tracks bids, offers, and trades in ABK Biomedical's shares on secondary markets.